https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18998 Wed 20 May 2020 07:08:07 AEST ]]> HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7415 Sat 24 Mar 2018 08:40:26 AEDT ]]> Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8213 Sat 24 Mar 2018 08:36:20 AEDT ]]> Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17176 Sat 24 Mar 2018 08:06:32 AEDT ]]> Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21393 = 30 kg/m²) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m²), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m²) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. Conclusion: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.]]> Sat 24 Mar 2018 08:05:04 AEDT ]]> Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Sat 24 Mar 2018 07:31:47 AEDT ]]> Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4800 Sat 24 Mar 2018 07:20:39 AEDT ]]> Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24426 Sat 24 Mar 2018 07:14:26 AEDT ]]>